solid portfolio newer therapi defend wide
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research sep
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
root provid supportive-car product kidney
diseas cancer patient free cash flow hover sale
firm benefit massiv cost-cut improv
manufactur strong newer blockbust like prolia/xgeva
futur blockbust cholesterol drug repatha defend
wide moat eros due biosimilar brand
biolog vulner biosimilar innov
brand drug also steal share tougher label
reimburs affect anemia drug epogen
aranesp sinc safeti concern emerg launch
biosimilar retacrit weigh sale
neutropenia drug biosimilar competit
year key longer-act drug neulasta began see
declin key market due two biosimilar
launch effect brand competitor pois
continu erod enbrel share enbrel patent run
think biosimilar humira expect unit
state could pull sale tnf class
address headwind invest heavili
more-effici manufactur undertaken massiv
cost-cut program defend margin reinvest research
develop promot new area like cardiolog
also purchas oral immunolog drug otezla fit
well enbrel franchis larg biosimilar
portfolio low manufactur cost make viabl biosimilar
player well
newer drug pipelin key counter
biosimilar version older drug prolia osteoporosi xgeva
fractur prevent cancer patient see
billion peak sale kyproli -- acquir onyx
pois becom billion product multipl myeloma
repatha cholesterol-low look like biggest opportun
estim billion peak sale also
bullish posit migrain drug aimovig phase
asthma drug tezepelumab early-stag cancer program like
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer supportive-car product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais fair valu estim per share
incorpor pend acquisit
immunolog drug otezla partli counter slight
decreas assumpt repatha follow strong
data compet drug inclisiran think firm
capabl averag top-lin growth
bottom-lin growth enbrel profit share
end signific cost-cut non-gaap
oper margin improv peak
nearli expect futur margin remain
near even addit invest
sell gener administr expens due
improv also give us increas confid
potenti biosimilar pipelin includ
nearli billion biosimilar sale
price power erod think enbrel sale
continu declin follow near-term benefit
price brand aranesp competit mircera
well epogen biosimilar launch weigh
declin begin extend
forecast biosimilar launch market
assum averag annual declin
neutropenia franchis neulasta
expect combin prolia/xgeva sale peak billion
forecast peak cholesterol-low sale billion
includ repatha sale well assum royalti
 praluent sale peak sale migrain drug
aimovig around billion peak global sale
osteoporosi drug even billion also see
newer cancer drug like blincyto imlyg smaller
opportun billion peak
risk surround share averag
cost equiti assumpt align capit cost
assumpt return equiti investor like
demand long run access
previous off-shore cash expect emphas
dividend share repurchas model slightli
declin gross debt near term note debt
level could easili increas undertak
large-scal acquisit assum pre-tax cost
debt reflect normal
confid capabl defend
bottom line key period weak legaci
product cost-cut manufactur innov help
trim oper cost howev abil grow
heavili depend repatha abil move past payer
restrict well futur potenti restrict
aimovig migrain even osteoporosi
therefor assign diversifi biotech medium
repatha sale assumpt well futur oper
margin key assumpt behind fair valu
estim base-cas scenario assum adjust
oper margin declin remain near
royalti sale praluent revenu
repatha praluent peak billion
bull-cas scenario assum adjust oper
margin remain assum obtain
royalti sale praluent
revenu hit billion result fair
valu estim per share
assum cost capit rate systemat
bear-cas scenario assum adjust oper
margin declin low repatha sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
competit anemia neutropenia drug
establish europ nascent gener
biosimilar pressur sever biolog
larg
manufactur difficulti cost clinic trial
product market creat high barrier entri
limit number entrant addit amgen
longer-act product aranesp neulasta help
defend biosimilar threat older product
billion praluent royalti persist
difficulti payer reimburs result fair
valu estim per share
market sever blockbust biolog therapi
oncolog immunolog market give
intang asset form foundat wide moat
one origin biotech launch innov
anemia neutropenia
begin epogen
longer-act product aranesp neulasta
launch firm decid acquir
immunex bring enbrel portfolio highli
profit biolog continu drive strong free cash
flow firm gener around sale expect
see steadi free cash flow margin level
return invest capit remain cost
capit forese futur
continu grow despit steadi regulatori
epogen aranesp sinc well biosimilar
also highli diversifi enbrel account
sale repatha otezla pois
top product sale strong growth
enbrel neutropenia drug counter epogen
aranesp headwind past year
osteoporosi cancer
indic reach blockbust statu
renal diseas drug sensipar onyx acquisit
multipl myeloma drug kyproli gener strong data
expand sale support european launch
competit like prevent signific uptak
see moat trend stabl think newli
launch product higher rate product
late-stag pipelin -- brand biosimilar -- allow
firm sustain strong roic new lower-cost
manufactur technolog aggress cost-cut
effort price volum pressur biosimilar
competit weigh heavili long-term margin
reimburs new competit brand
biosimilar biggest headwind moat
trend reimburs dialysi drug epogen bundl
dialysi product although contract
competit price margin pressur
product also among oldest --
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
also bullish abil compet
biosimilar market given firm effici manufactur
practic establish oncolog immunolog salesforc
regulatori legal expertis advanc pipelin
assum partner allergan hold
share global biosimilar market believ
manufactur improv could boost
biosimilar emerging-market opportun creat
profit -- market biolog mani among
first see biosimilar competit key patent
epogen neulasta expir
three product account top
line biosimilar competit europ mild
impact epogen sale focus
 brand neulasta shield
biosimilar competit neulasta sale
 howev epogen biosimilar
biosimilar neulasta coheru
launch earli overal expect
averag annual sale declin epogen
neutropenia franchis addit arthriti
psoriasi drug enbrel see high level new
competit assum double-digit sale declin
begin ahead humira biosimilar launch
top
howev regard pipelin product think amgen
turn corner think firm abl
line despit pressur current
blockbust histor high failur rate
pipelin particularli oncolog pipelin
decis return brodalumab
right astra due higher rate suicid also hit
late-stag pipelin howev cholesterol drug
repatha launch europ
despit slow start expect antibodi class
could gener billion peak sale
sanofi/regeneron praluent remain well ahead key
even approv cardiovascular
side effect could limit broad uptak drug
bone-form mechan action could complement
prolia migrain drug aimovig launch
could see billion peak potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pipelin product sinc
launch prolia/xgeva cholesterol drug repatha
migrain drug aimovig reviv
enthusiasm firm research engin
obiosimilar market europ sinc
biosimilar larger impact
version epogen neulasta hit
acquisit decod give firm
abil identifi potenti new drug target valid
human genet
improv manufactur effici
benefit gross margin also could give firm
cost advantag nascent biosimilar market
alreadi launch two product europ
oth payoff billion acquisit
onyx highli depend success kyproli
johnson johnson/genmab darzalex
bcma-target therapi like strong
lack focu biotech peer
drug target larg market like osteoporosi
cardiolog specialti market like immunolog
oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end held billion cash
billion debt expect compani gener
roughli billion free cash flow annual next
year combin one-tim repatri
off-shore cash end
suffici handl debt come due well
share-repurchas program billion repurchas
dividend program dividend increas
rise
biosimilar uptak remain biggest risk
neulasta epogen biosimilar
launch regulatori reimburs chang
could continu plagu aranesp epogen includ
medicar dialysi reimburs cut enbrel key
growth driver grow competit
rheumatoid arthriti psoriasi could weigh
firm market share price power evapor
overal price power could wane propos
medicar part reimburs
implement given firm relianc medicar
high proport sale addit sever
newer product enter highli competit market
prolia compet establish drug novarti
reclast cheaper gener bisphosphon vectibix
compet roch avastin eli lilli
kyproli lead proteasom inhibitor velcad
posit comparison fail differenti
kyproli first-lin set billion
acquisit onyx could prove expens repatha
shown signific abil reduc advers cardiovascular
event benefit may enough loosen payer
restrict limit patient access drug aimovig
also enter crowd market similar drug
entrant eager discount price gain share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mr robert bradwayceo/chairman board/
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
assign amgen standard mark stewardship
firm engin struggl churn
promis drug candid sinc launch prolia/xgeva
believ new blood might benefici firm
product futur share perform sale
profit skyrocket reign ceo
chairman kevin sharer signific multipl
compress led flat perform firm share
tenur former presid bob bradway
replac sharer ceo may board chairman
start bradway advanc
sinc arriv vice presid oper
wish firm select someon longer
record pharmaceut industri
bradway year think
experi would particularli use
firm face steep biosimilar competit need
cohes strategi hope keep top-lin growth
posit territori said cfo david melin
appear make necessari cost cut achiev
left posit head research develop
posit sinc replac roger
perlmutt februari execut vice presid
global commerci oper anthoni hooper also
retir howev encourag progress
new leadership new head david rees
medic background serv sinc
new oper head murdo gordon join
bristol-my squibb formerli chief commerci offic
made sever shareholder-friendli move
recent histori share repurchas tender offer level
fair valu estim appear good use
cash quarterli dividend grew roughli annual
initi level continu grow
double-digit rate howev remain wari firm
compens polici reward execut easili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
manipul ep growth instead return invest
capit board structur enough healthcare-rel
experi member former ceo
robert eckert phillip ceo greg garland
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bristol sale otezla fair price
bristol-my squibb divest psoriasi drug otezla
billion repres price close
fair valu estim drug expect
major impact fair valu estim moat
firm deal appeas anti-trust
concern regul pend acquisit
celgen bristol follow announc divest
bristol guid close celgen deal late
slightli ahead previou guidanc think
updat guidanc reason
surpris potenti ownership
bristol pipelin psoriasi drug bm celgen
otezla caus anti-trust concern feder trade
commiss bristol face fire sale price otezla
continu view stronger two
psoriasi drug expect drug reach market
asset combin sever pipelin
perspect otezla add support
near-term growth project three-year compound
growth rate drug along exclus
least longer market also
strong presenc understand psoriasi market
develop commerci enbrel
mean rel smooth transit market otezla
longer term expect take share
otezla base stronger efficaci seen earli stage
studi drug offer conveni oral
administr addit expect
take share biolog psoriasi drug base easier
oral dose versu inject superior efficaci
complet review outlook psoriasi
remain secur innov counter price gener
headwind acceler
rais fve base solid result
intern biosimilar portfolio progress jul
rais fair valu estim per
share follow solid second-quart result
driver fair valu estim increas near-term
enbrel sale strength due probabl unsustain net
price increas year well promis launch
sever biosimilar europ unit
state saw low-single-digit volum growth
quarter well intern sale growth place
blame overal sale declin mostli lower
price repatha older product face
biosimilar competit biosimilar competit
like intensifi possibl addit neulasta
competitor enter market later year
repatha lower price begin annual later
year encourag strong repatha demand amgen
biosimilar launch earli data firm novel
oncolog pipelin although remain cautiou
extrapol data hand patient multi-billion-
prolia pipelin therapi like help defend
stabl wide moat pressur biosimilar
competit think share
under-valued recent price
biosimilar competit biosimilar repres
new threat opportun firm neulasta
biosimilar competit key headwind sale
stem roughli volum declin
price declin maintain
share long-act market end quarter
unit differenti onpro deliveri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
system stabl first quarter expect
addit competit lead steadi double-digit
declin franchis franchis face
new biosimilar epogen
closer declin remov one-tim benefit
declin mostli due lower price
extend contract expect pressur
remain throughout double-digit declin
continu futur year hand
recent first market biosimilar version roch
herceptin avastin biosimilar version
herceptin humira led
million sale europ quarter biosimilar
portfolio also expand expect phase data
biosimilar rituxan third quarter approv
biosimilar remicad decemb
earli oncolog pipelin also progress data
bispecif bcma-target therapi
updat june maintain respons rate
chosen ug dose level patient improv
mrd-neg complet respons rate
commerci potenti drug look limit due
difficult continu infus potenti once-weekli
version data next spring
drug impress data lung
cancer patient see
respons treatment rais fair valu estim
news lung cancer
patient hold mutat model
probabl approv nearli billion probability-
weight sale year forecast expect
updat lung cancer data septemb still
test higher dose also combin drug
antibodi plan start pivot monotherapi
studi immin also announc seen
respons one colorect one appendic cancer
patient chang estim see
extens data addit competit landscap
could becom crowd behind mirati
data end year target
therapi merck/moderna enter
combin phase trial june keytruda kra
senat financ committe chairman chuck grassley
democrat rank member ron wyden post
prescript drug price reduct act tuesday
although final bill need proceed
mark-up thursday get major vote full
committe could see chang proce
senat floor vote like mean bipartisan
agreement reach prior post share price
drug firm larg unmov news
think progress senat make less like
sever hh rule intern price benchmark
medicar part implement also mean
increasingli like legisl could hold price
increas extent make fair valu
estim chang news continu watch
updat senat follow thursday mark-up
hous like propos legisl
septemb caution possibl bipartisan
bill could pass senat fail hous
progress democrat will compromis
certain issu exampl medicar part direct
negoti includ pdpra regardless
expect overhang drug stock next sever
month drug price overhaul remain key topic
washington result continu see industri
under-valued despit strong product increasingli
overal propos pdpra similar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
discuss recent analysi rebat rule dead
signific benefit pdpra compar
rebat rule cost congression budget offic
cbo estim rebat rule would result
billion extra feder spend year
assum current rebat withheld contrast
cbo estim pdpra would save taxpay
billion year billion save
medicaid mostli increas maximum rebat
billion save medicar within medicar
save larg split part redesign
billion inflation-reb polici billion
would forc drugmak pay addit rebat drug
medicar part part price increas
exceed inflat cpi-u roughli annual
addit two medicar polici would help
beneficiari lower pocket cost premium
total billion year cbo also assum
inflation-reb provis would reduc drug cost
patient privat insur part redesign
would substanti effect patient
think unclear impact pdpra could
patient cover privat insur drugmak could
continu rais price privat market simpli pay
addit rebat necessari medicar
spend dashboard one saw averag annual price
increas
neulasta newer blockbust bristol opdivo
merck keytruda top annual price
increas part expect could
drug higher list price increas could
impact dashboard spend data indic averag
annual price increas top drug around
rebat rule dead suppli chain benefit drug firm
pressur estim drug firm exposur
anoth key part pdpra drug manufactur
perspect medicar part redesign could
implement would hit firm
expens drug hardest chang would cap out-
of-pocket cost previous patient paid drug cost
catastroph phase limit
patient enter catastroph coverag phase drug
firm would hook drug cost
elimin current coverag gap discount drug firm
pay cost coverag gap introduc
new respons higher spend level
discuss recent research see firm like gilead
hepat hiv treatment bristol/celgen cancer
therapi revlimid potenti expos peer
among highest-profil provis pdpra
propos cap medicar part part price increas
inflationari level begin excess price
increas would need return medicar form
rebat part expect larg
impact even firm high exposur channel
biggest drug program take
larg price increas reimburs system alreadi
discourag instead reli high launch price
profit exampl among top drug medicar
part spend accord medicar drug
first report juli axio trump administr
plan final propos rule alter flow
drug rebat purchas medicar part plan
rule would chang busi model
pharmaci benefit manag requir negoti
discount pass directli beneficiari
point sale rather use mechan lower
cost insur plan overal led ralli
pbms/insur distributor drug stock sank
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
investor wonder presid donald trump focu
turn next take rebat reform tabl put
pressur congress particularli bipartisan senat
financ committe team chuck grassley ron wyden
reveal drug-pric packag month stand
chanc pass chamber potenti reform
like reduc cost medicar patient also look
modest payer drug firm
think remain propos review
budget offic -- medicar part intern price
index -- unlik implement even final
congress power block rule judici review
could find massiv demonstr overextens
author center medicar medicaid
innov cmmi
altern expect senat drug price packag
could includ part reform also includ cap
out-of-pocket spend medicar part anticip
propos would see widespread support
policymak result higher likelihood
success think chang would manag
drug firm effect achiev bipartisan
polici goal lower healthcar cost american
addit detail analysi effect
rebat rule elimin pleas see report rebat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
